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  Ofioxacin was administered orally at a daily dosage of 300 mg and・600 mg in three divided
doses for 14 days t．o 24 and 60 patients with chronic complicated urinary infections， respectively，
in order to cvaluate the therapeutic e田cacy． The clinical efficacy was evaluatcd according to the
criterion proposed by the UTI Committee in Japan and its efficacy was evaluated in 84 cases． ln
the group of 24．patients receiving a daily dosage of 300 mg， the clinical effectiveness after a 5－day
treatment was excellent in 13 cases and moderate in 7 cases． The overall．clinical efficacy was
83．8％． ln the group of 60 patients receiving a daily dosage of 600 mg， the rate of overall
clinical efficacy after a 5－day treatment was 83．3／aOo， being excellent in 23 cases and moderate in
27 cases． The eradication rate was 85．3％ and 92．5％ by 300 mg and 600mg dosages of ofloxacin，
respective1y： As adverse reactions， anorexia and nausea occurred in 2 cases． Laboratory anom－
alies consisted of 1 case of s｝ight and transient elevation of transaminase， and 1 case of elevated
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serum creatlmne．
（Ac．ta Urol． Jpn． 36： 725－730， 1990）












































ratia spP．3株， Acinetobacter spP．3株， Flavobac－
terium spP・2株， K・oxytoca， Citrobacter spP，
Table 1． Underlying disease













Tota1 84 （100 ）
Table 2． Overall clinical efficacy of OFLX in complicated UTI （100 mgx3／day）
             Pyur孟a
aacteriuria Cleared Decreased Unchanged
Effect of
b≠モ狽?窒奄浮窒奄
Eliminated 13 3 1 17 （71％）
Decreased
Replaced 2 1 1 4 （17％）
Unchanged 1 2 3 （13％）
壁ect on pyuria 16（67％） 4（17％） 4（17％）
Patient tota1
@   24
［＝＝］Excellent 13（54，2％｝
［＝＝コM・d・・a・・ 7（29．2％） OveraH effectjveness rate
@    20／24（83．3％）
E＝＝＝＝コP… 4（16，6％）
Table 3．
                 打林，ほか：複雑性尿路感染症・OFLX













lst group （Catheter indwelt）
2nd group （Post prostatectomy）
3rd group（Upper UTI）
4th group（Lower UTI）

























6th group（No catheter indwelt）













Tota1 24 （10e ％） 13 7 4 83．3 ％
Table 4．Bacteriological response to OFLIX in complicated UTI （IOO mgx3／day）




























































Tota1 34 29 （85．3） 5
Table 5．
  ＊：Regardless of bacterial count
Overall clinical efficacy of OFLX inomplicated LTTI （200 mg／3／day）
             Pyuria
aacteriuria Cleared Decreased Unchanged
Effect of
b≠モ狽?窒奄浮窒奄
Eliminated 23 7 9 39 （65％）
Decreased
Replaced 6 5 4 15 （25％）
Unchanged 2 4 6 （10％）
E匠ect on pyuria 31（52％） 12 （20％） 17（28％） Patient tota1@   60
Exce11ent 23〔38．3％）
Moderate 27（45．0％） Overaii effectiveness rate
@    50／60 （83．3％）
Poor 10（16．7％）
Streptococcus spp・各1株はいずれも100％の除菌
率を示し，P． aeruginosa 2株 S． aureus， E．
faecalis， E． co！i各1株が存続した（Table 4）．
  1日600mg投与による慢性複雑性尿路感染症60










尿中より分離されたE．coli lO株， K． pneumoniae
9株，Streptococcus spP・， Citrobacter spP・昏S
6号 1990年
．株， Enterobacter spP． 4株， S． epidermidis，














   total）
                 Overall
Excellent Moderate Poor Effectiveness








      Sub tota1
7 （11．7％）
5（8．3％）























6th group（No catheter indwelt）
      Sub tota1














Tota1 60 （ユ00男） 23 27 ユ0 83．3％
Table 7． Bacteriological responSe of OFLX in complicated UTI （200 mg／3fday）

















































































Tota1 80 74 （ 92．5 ） 6
＊：Regardless of bacterial count
打林，ほか：複雑性尿路感染症・OFLX 729
Table 8． lncidence of adverse reactions
Cace dge           Underlying
No． Sax Diagnosiis disehseSymtom Severity Da七e ononset
Relation to
Ofloxacin
26 75 M C． C． C． B．P．H． GcrT t 23一一． 50U／m1 5 clay Probably related
42 43 M C． C． C． N． B． Loss of appeti七e 十 4 day Probably related
78 72 F C． C． C． N． B．
Cr T
Nausea
1．9 一 2． 5mg／di 11 day Possibly related
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